Piotr J. Wysocki

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Thomas Powles, Kobe Yuen, Silke Gillessen et al. · Nature Medicine · 2022 · 242 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid, Seock‐Ah Im, Anne Armstrong et al. · Journal of Clinical Oncology · 2021 · 110 citations

Medicine, Oncology, Pharmacology +17

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2024 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Christopher J. Sweeney, Silke Gillessen, Dana E. Rathkopf et al. · Cancer Research · 2020 · 62 citations

Medicine, Pharmacology, Pharmacotherapy +17

Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice

Nadzieja Drela, Ahmad Jalili, Rafał Kamiński et al. · Cancer Immunology Immunotherapy · 2004 · 50 citations · Full text

Medicine, Immunology, Oncology +16